ABSTRACT
The COVID 19 crisis and geopolitical ruptures of recent years have highlighted the importance of operations and supply chain management (OSCM) to firms and society. How do OSCM executives make decisions under uncertainty, and how do they balance the competing needs of various stakeholders? The behavioral agency model (BAM), which has been widely used in the management literature, focuses on the executive as the unit of analysis, like the behavioral science research in which it is embedded;by contrast, much of the supply chain risk management research has examined risk at the level of the firm. We review BAM literature and its core constructs, refine its original predictions, identify OSCM executive decision contexts that could take advantage of BAM, and highlight research opportunities using BAM. We aim to provide a platform for further risk research applying BAM in the domain of OSCM executive decision-making.
ABSTRACT
The COVID-19 pandemic requires urgent decisions regarding treatment policy in the face of rapidly evolving evidence. In response, the South African Essential Medicines List Committee established a subcommittee to systematically review and appraise emerging evidence, within very short timelines, in order to inform the National Department of Health COVID-19 treatment guidelines. To date, the subcommittee has reviewed 14 potential treatments, and made recommendations based on local context, feasibility, resource requirements and equity. Here we describe the rapid review and evidence-to-decision process, using remdesivir and dexamethasone as examples. Our experience is that conducting rapid reviews is a practical and efficient way to address medicine policy questions under pandemic conditions.